Home  /  Resource Library  /  IBRUTINIB-RITUXIMAB AND VENETOCLAX (IRV) FOLLOWED BY RISK-STRATIFIED R-HYPERCVAD/MTX IN YOUNG PATIENTS WITH UNTREATED MANTLE CELL LYMPHOMA – PHASE-II WINDOW-2 TRIAL

IBRUTINIB-RITUXIMAB AND VENETOCLAX (IRV) FOLLOWED BY RISK-STRATIFIED R-HYPERCVAD/MTX IN YOUNG PATIENTS WITH UNTREATED MANTLE CELL LYMPHOMA – PHASE-II WINDOW-2 TRIAL

ICML 2023